establishing a committee to study the feasibility of establishing experimental treatment centers in New Hampshire and the oversight thereof.

Summary

The bill adds a new chapter that authorizes health‑care providers to operate experimental treatment centers for patients who have a physician’s recommendation to use a drug, biologic, or device that has completed Phase I trials but is not yet FDA‑approved. It sets detailed eligibility and informed‑consent requirements and protects physicians and providers from licensing actions based solely on offering these treatments. The law does not require insurers or the state to pay for the therapies.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share